Baraclude Oral Tablet 0.5Mg Drug Medication Dosage Information
show timeout overlay link

Your Session Is About to Expire

This online session is about to expire due to inactivity. Click Continue to return to page.

  • myWeekly Ad

Baraclude: Oral tablet (0.5mg)

Also see:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics

Visit Drug Summary Page
Drug Image file DrugItem_7431.JPG
Baraclude 0.5mg Tab
Bristol Myers Squibb Co
Pill Identification: BMS  |  1611

What is this Medicine?

ENTECAVIR (en TE ka veer) is an antiviral medicine. It is used to treat chronic hepatitis B. This medicine will not cure or prevent hepatitis B infection.

CVS Pharmacy Patient Statistics for Baraclude: Oral tablet(0.5mg)
Generic vs. Brand Name Usage*
*Brand contains same active ingredient but may not represent FDA-approved generic equivalent
Usage By Strength
In-Depth Information

Baraclude 0.5mg Tablet

NDC: 000031611
  • Prescription Required
  • Not a Controlled Drug
    (CSA Schedule)
  • FDA Approved




FDA approved for the following conditions:
Hepatitis B Infection

Storage Information
Store in a dry place
Store at 77 degrees F; excursions permitted to 59-86 degrees F
Baraclude 0.5mg Tablet
Drug Image file DrugItem_7431.JPG
Bristol Myers Squibb Co
Pill Identification: BMS  |  1611
Shape: triangular (3-sided)
Color: white

Reported Side Effects for Baraclude 0.5mg Tablet

Upset Stomach Incidence:
<1.0%*
Severity: MILD
Onset: EARLY
Kidney Failure Incidence:
<1.0%*
Severity: SEVERE
Onset: DELAYED
Vomiting Incidence:
<1.0%*
Severity: MILD
Onset: EARLY
Low Albumin In Blood Incidence:
<1.0%*
Severity: MODERATE
Onset: DELAYED
Low Platelet Count Incidence:
<1.0%*
Severity: MODERATE
Onset: DELAYED
Inability To Sleep Incidence:
<1.0%*
Severity: MILD
Onset: EARLY
Loose Stools Incidence:
<1.0%*
Severity: MILD
Onset: EARLY
Drowsiness Incidence:
<1.0%*
Severity: MILD
Onset: EARLY
Upset Stomach Incidence:
<1.0%*
Severity: MILD
Onset: EARLY
Skin Rash Incidence:
>1.0%*
Severity: MILD
Onset: EARLY
Tired Incidence:
1.0-3.0%*
Severity: MILD
Onset: EARLY
Stomach Pain Incidence:
>1.0%*
Severity: MILD
Onset: EARLY
Headache Incidence:
2.0-4.0%*
Severity: MILD
Onset: EARLY
Increased Blood Sugar Incidence:
2.0-3.0%*
Severity: MODERATE
Onset: DELAYED
Elevated Hepatic Enzymes Incidence:
2.0-12.0%*
Severity: MODERATE
Onset: DELAYED
High Bilirubin Level Incidence:
2.0-3.0%*
Severity: MODERATE
Onset: DELAYED
Lightheadedness Incidence:
>3.0%*
Severity: MILD
Onset: EARLY
Glycosuria Incidence:
4.0%*
Severity: MODERATE
Onset: EARLY
Blood In The Urine Incidence:
9.0%*
Severity: MODERATE
Onset: DELAYED
Infection Incidence:
10.0%*
Severity: MILD
Onset: DELAYED
Hepatic Encephalopathy Incidence:
10.0%*
Severity: SEVERE
Onset: DELAYED
Fever Incidence:
14.0%*
Severity: MILD
Onset: EARLY
Extra Abdominal Fluid Incidence:
15.0%*
Severity: MODERATE
Onset: DELAYED
Fluid Retention Incidence:
16.0%*
Severity: MODERATE
Onset: DELAYED
*This is an approximate aggregated range of reported side effects from clinical studies performed on this drug. Your experience with this drug may be different.
Daily Life Interactions for Baraclude 0.5mg Tablet

Elements of your daily lifestyle may have an effect on the medications you are taking. Drug interactions can result in unwanted side effects, reduce the effectiveness of your medicine or possibly increase the action of a particular medicine.

Moderate Lifestyle Interaction
Marijuana and Baraclude 0.5mg Tablet(Entecavir)
Marijuana and Nucleoside reverse transcriptase inhibitors(Entecavir)
Although an interaction is possible, these drugs may be used together. In therory, side effects from Marijuana, Medical may get worse if you take Anti-retroviral nucleoside reverse transcriptase inhibitors (NRTIs). However, the importance of this interaction is not known. Notify your health care provider if you notice increased fatigue, nausea, vomiting, or any other unusual effects.
Pregnancy & Lactation Information
FIRST Trimester

Class C - Animal studies have shown an adverse effect and there are no adequate and well-controlled studies in pregnant women. OR No animal studies have been conducted and there are no adequate and well-controlled studies in pregnant women.

SECOND Trimester

Class C - Animal studies have shown an adverse effect and there are no adequate and well-controlled studies in pregnant women. OR No animal studies have been conducted and there are no adequate and well-controlled studies in pregnant women.

THIRD Trimester

Class C - Animal studies have shown an adverse effect and there are no adequate and well-controlled studies in pregnant women. OR No animal studies have been conducted and there are no adequate and well-controlled studies in pregnant women.

Lactation

Caution - Not enough information is available to rule out harm to infants when this drug is taken by nursing mothers.


Learning More About
Visit the Drug Summary page where you can:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics
Learn More
Patient Experiences with Baraclude

We want to help you stay educated about the medications you are taking. View other
patient's observations and share your own.

Be sure to consult your health care provider before taking any medications. Other
patient's comments should not be considered medical advice or health care provider
recommendations.